Publication

Clinical Validation of the Cervista HPV HR Test According to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Cancer Screening

Boers, A., Wang, R., Slagter-Menkema, L., van Hemel, B. M., Ghyssaert, H., van der Zee, A. G. J., Schuurs-Wisman, G. B. A. & Schuuring, E., Dec-2014, In : Journal of Clinical Microbiology. 52, 12, p. 4391-4393 3 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

DOI

This study demonstrates that both the clinical sensitivity and specificity of the Cervista HPV HR test for high-risk human papillomavirus (HPV) detection are not inferior to those of the Hybrid Capture 2 (HC2) test. The intra- and interlaboratory reproducibilities of Cervista were 92.0% (kappa, 0.83) and 90.4% (kappa, 0.80), respectively. The Cervista HPV HR test fulfills all the international HPV test requirements for cervical primary screening purposes.

Original languageEnglish
Pages (from-to)4391-4393
Number of pages3
JournalJournal of Clinical Microbiology
Volume52
Issue number12
Publication statusPublished - Dec-2014

    Keywords

  • HIGH-RISK HPV, HYBRID CAPTURE 2, CYTOLOGY, WOMEN, PERFORMANCE, ASSAY, DNA, EXPERIENCE, AGE

View graph of relations

Download statistics

No data available

ID: 15061445